Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C20H19NO2 |
| Molecular Weight | 305.3704 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC1=C(O)C=C2[C@H](CC3=CC=CC4=C3C=CC=C4)NCCC2=C1
InChI
InChIKey=YGCQFKVNIBDJFW-SFHVURJKSA-N
InChI=1S/C20H19NO2/c22-19-11-15-8-9-21-18(17(15)12-20(19)23)10-14-6-3-5-13-4-1-2-7-16(13)14/h1-7,11-12,18,21-23H,8-10H2/t18-/m0/s1
| Molecular Formula | C20H19NO2 |
| Molecular Weight | 305.3704 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:32:50 GMT 2023
by
admin
on
Sat Dec 16 11:32:50 GMT 2023
|
| Record UNII |
PW8215U0ZU
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
626252-75-3
Created by
admin on Sat Dec 16 11:32:50 GMT 2023 , Edited by admin on Sat Dec 16 11:32:50 GMT 2023
|
PRIMARY | |||
|
PW8215U0ZU
Created by
admin on Sat Dec 16 11:32:50 GMT 2023 , Edited by admin on Sat Dec 16 11:32:50 GMT 2023
|
PRIMARY | |||
|
9861304
Created by
admin on Sat Dec 16 11:32:50 GMT 2023 , Edited by admin on Sat Dec 16 11:32:50 GMT 2023
|
PRIMARY | |||
|
DTXSID701026703
Created by
admin on Sat Dec 16 11:32:50 GMT 2023 , Edited by admin on Sat Dec 16 11:32:50 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR | |||
|
TARGET->INHIBITOR OF EXPRESSION |
|
||
|
SALT/SOLVATE -> PARENT | |||
|
TARGET->INHIBITOR OF EXPRESSION |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
CKD-712 showed organ-protective effect by reducing serum glutamate-oxaloacetate transaminase, glutamate-pyruvate transferase, blood urea nitrogen, and creatinine levels. CKD-712 also prevented histological damage to the lung and liver. In this same model, CKD-712 showed anti-inflammatory effects through decreases in tumor necrosis factor-.ALPHA. and interleukin-6 in the blood and reduced translocation of nuclear factor-.KAPPA.B to the nuclei of lung cells. CKD-712 administration also diminished infiltration of leukocytes into the lung and liver. Taken together, these results show that CKD-712 has excellent potential as an effective medicine for sepsis.
|
||
|
ACTIVE MOIETY |
The activation of ERK, JNK, p38, IRF3 and Akt was measured by western blotting. CKD-712 inhibited the NF-.KAPPA.B signaling triggered by LPS. The activation of ERK, JNK, p38 or IRF3 was not inhibited by CKD-712. On the contrary the activation of these molecules was augmented slightly. The activation of Akt with stimulation of LPS was also enhanced with CKD-712 pre-treatment at lower concentration, but was inhibited at higher concentration. We suggest that during TLR4 signaling CKD-712 inhibits NF-.KAPPA.B activation. However, CKD-712 augmented the activation of Akt as well as Map kinases.
|
